THE ROLE OF FECAL CALPROTECTIN IN INVESTIGATING INFLAMMATORY BOWEL DISEASES

被引：19

作者：

Erbayrak, Mustafa ^{[1
]}

Turkay, Cansel ^{[1
]}

Eraslan, Elife ^{[1
]}

Cetinkaya, Hulya ^{[2
]}

Kasapoglu, Benan ^{[3
]}

Bektas, Mehmet ^{[2
]}

机构：

[1] Fatih Univ Hosp, Dept Gastroenterol, Ankara, Turkey

[2] Ankara Univ Hosp, Dept Gastroenterol, Ankara, Turkey

[3] Fatih Univ Hosp, Dept Internal Med, Ankara, Turkey

来源：

CLINICS | 2009年 / 64卷 / 05期

关键词：

Inflammatory bowel diseases; Irritable bowel syndrome; Fecal calprotectin; CROHNS-DISEASE; ULCERATIVE-COLITIS; SMOKING; MARKER;

D O I：

10.1590/S1807-59322009000500009

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

INTRODUCTION: Invasive and non-invasive tests can be used to evaluate the activity of inflammatory bowel diseases. OBJECTIVE: The aim of the present study was to investigate the role of fecal calprotectin in evaluating inflammatory bowel disease activity and the correlation of fecal calprotectin with the erythrocyte sedimentation rate and C reactive protein values in inflammatory bowel disease. METHOD: Sixty-five patients affected with inflammatory bowel disease were enrolled. Twenty outpatients diagnosed with inflammatory bowel disease comprised the control group. RESULTS: In the present study, all patients in the control group had an fecal calprotectin value lower than the cut-off point (50 mg/kg). CONCLUSION: In conclusion, fecal calprotectin was found to be strongly associated with colorectal inflammation indicating organic disease. Fecal calprotectin is a simple and non-invasive method for assessing excretion of macrophages into the gut lumen. Fecal calprotectin values can be used to evaluate the response to treatment, to screen asymptomatic patients, and to predict inflammatory bowel disease relapses.

引用

页码：421 / 425

页数：5

共 14 条

[1]

Impact of cessation of smoking on the course of ulcerative colitis [J].

Beaugerie, L ;

Massot, N ;

Carbonnel, F ;

Cattan, S ;

Gendre, JP ;

Cosnes, J .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2001, 96 (07) :2113-2116

[2]

Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease [J].

Costa, F ;

Mumolo, MG ;

Ceccarelli, L ;

Bellini, M ;

Romano, MR ;

Sterpi, C ;

Ricchiuti, A ;

Marchi, S ;

Bottai, M .

GUT, 2005, 54 (03) :364-368

[3]

FAGERHOL MK, 1980, SCAND J HAEMATOL, V24, P393

[4]

Faecal calprotectin in the assessment of Crohn's disease activity [J].

Gaya, DR ;

Lyon, TDB ;

Duncan, A ;

Neilly, JB ;

Han, S ;

Howell, J ;

Liddell, C ;

Stanley, AJ ;

Morris, AJ ;

Mackenzie, JF .

QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2005, 98 (06) :435-441

[5]

JEWELL DP, 2002, ULCERATIVE COLITIS S, V103, P2039

[6]

KRUIS W, 1984, GASTROENTEROLOGY, V87, P1

[7]

Effects of current cigarette smoking on clinical course of Crohn's disease and ulcerative colitis [J].

Odes, HS ;

Fich, A ;

Reif, S ;

Halak, A ;

Lavy, A ;

Keter, D ;

Eliakim, R ;

Paz, J ;

Broide, E ;

Niv, Y ;

Ron, Y ;

Villa, Y ;

Arber, N ;

Gilat, T .

DIGESTIVE DISEASES AND SCIENCES, 2001, 46 (08) :1717-1721

[8]

COATED MESALAZINE (5-AMINOSALICYLIC ACID) VERSUS SULPHASALAZINE IN THE TREATMENT OF ACTIVE ULCERATIVE-COLITIS - A RANDOMIZED TRIAL [J].

RACHMILEWITZ, D .

BMJ-BRITISH MEDICAL JOURNAL, 1989, 298 (6666) :82-86

[9]

Determination of faecal calprotectin, a novel marker of organic gastrointestinal disorders [J].

Roseth, AG .

DIGESTIVE AND LIVER DISEASE, 2003, 35 (09) :607-609

[10]

SANDS BE, 2002, CROHNS DIS SLEISENGE, V103, P2005

← 1 2 →